149 related articles for article (PubMed ID: 38888812)
21. Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
Hijiya N; Mauro MJ
Cancer Manag Res; 2023; 15():873-891. PubMed ID: 37641687
[TBL] [Abstract][Full Text] [Related]
22. Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review.
Atallah E; Saini L; Maegawa R; Rajput T; Corbin R; Viana R
Ther Adv Hematol; 2023; 14():20406207221150305. PubMed ID: 38105770
[TBL] [Abstract][Full Text] [Related]
23. BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib.
Leyte-Vidal A; Garrido Ruiz D; DeFilippis R; Leske IB; Rea D; Phan S; Miller KB; Hu F; Mase A; Shan Y; Hantschel O; Jacobson MP; Shah NP
Blood; 2024 Apr; ():. PubMed ID: 38643492
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
[TBL] [Abstract][Full Text] [Related]
25. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
Okabe S; Moriyama M; Gotoh A
Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
[TBL] [Abstract][Full Text] [Related]
26. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
Chee L; Lee N; Grigg A; Chen M; Schwarer A; Szer J; Ratnasingam S; Raj S; Lukito P; Yeung D; Hughes T; Shanmuganathan N
Intern Med J; 2024 Jun; ():. PubMed ID: 38884158
[TBL] [Abstract][Full Text] [Related]
28. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
Cortes JE; Hochhaus A; Takahashi N; Larson RA; Issa GC; Bombaci F; Ramscar N; Ifrah S; Hughes TP
Future Oncol; 2022 Dec; 18(38):4161-4170. PubMed ID: 36524980
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report.
Alshurafa A; Afshan Adil ; Yassin MA
Case Rep Oncol; 2024; 17(1):96-100. PubMed ID: 38229976
[TBL] [Abstract][Full Text] [Related]
30. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
Häselbarth L; Karow A; Mentz K; Böttcher M; Roche-Lancaster O; Krumbholz M; Jitschin R; Mougiakakos D; Metzler M
Cancer Immunol Immunother; 2023 Jun; 72(6):1661-1672. PubMed ID: 36602564
[TBL] [Abstract][Full Text] [Related]
31. Asciminib for chronic myeloid leukaemia: Next questions.
Shanmuganathan N; Hughes TP
Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
[TBL] [Abstract][Full Text] [Related]
32. Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.
Okabe S; Gotoh A
BMC Cancer; 2023 Sep; 23(1):827. PubMed ID: 37670241
[TBL] [Abstract][Full Text] [Related]
33. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
Garcia Molina A
Farm Hosp; 2024 Apr; ():. PubMed ID: 38679535
[TBL] [Abstract][Full Text] [Related]
34. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing
Gleixner KV; Filik Y; Berger D; Schewzik C; Stefanzl G; Sadovnik I; Degenfeld-Schonburg L; Eisenwort G; Schneeweiss-Gleixner M; Byrgazov K; Sperr WR; Mayer J; Lion T; Valent P
Am J Cancer Res; 2021; 11(9):4470-4484. PubMed ID: 34659899
[TBL] [Abstract][Full Text] [Related]
35. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Hochhaus A; Gambacorti-Passerini C; Abboud C; Gjertsen BT; Brümmendorf TH; Smith BD; Ernst T; Giraldo-Castellano P; Olsson-Strömberg U; Saussele S; Bardy-Bouxin N; Viqueira A; Leip E; Russell-Smith TA; Leone J; Rosti G; Watts J; Giles FJ;
Leukemia; 2020 Aug; 34(8):2125-2137. PubMed ID: 32572189
[TBL] [Abstract][Full Text] [Related]
36. Asciminib: First Approval.
Deeks ED
Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
[TBL] [Abstract][Full Text] [Related]
37. Asciminib in chronic myeloid leukemia.
Assanto GM; Scalzulli E; Breccia M
Drugs Today (Barc); 2022 Oct; 58(10):479-489. PubMed ID: 36305542
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
39. Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Padala S; Cortes J
Haematologica; 2023 Nov; 108(11):2913-2918. PubMed ID: 37102603
[TBL] [Abstract][Full Text] [Related]
40. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
